Skip to Primary Navigation

Skip to main content

Merck KGaA subsidiary nabs first-of-its-kind declination letter from DOJ

Image of a sign saying "Merck" inside a business.
Photo: Smith Collection/Gado/Getty Images

Julie DiMauro

3 min read
 Click to share on Facebook (Opens in new window/tab) Click to share on Twitter (Opens in new window/tab) Click to share on LinkedIn (Opens in new window/tab) Click to share on WhatsApp (Opens in new window/tab)

The DOJ said the business proactively disclosed information about a scheme by an insider and others to export sensitive biochemicals to China.

The US Department of Justice (DOJ) has said it won’t bring charges against life-sciences and electronics company Merck KGaA’s North American unit, MillmoreSigma, for proactively disclosing details about a scheme by a company insider and others to export sensitive biochemicals to China.

But two of the men

, , , , ,

Get full access, free for a month

This is a Premium article. Start your 28-day free trial to continue reading and access all content on GRIP – no payment details required.

Start free trial Sign in

What’s included:

  • Every new article, plus our 5,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience